Back to Report Store Home

Chronic Respiratory Disease Drug Development Pipeline Review, 2018

  • Published: Nov-2018
  • Report Code: GBIHC050IDB
  • Report Format: pdf

Description

List of Figures

Figure 1: Number of Products under Development for Asthma

Figure 2: Number of Products under Development by Companies, Asthma

Figure 3: Number of Products under Development by Universities/Institutes, Asthma

Figure 4: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD

Figure 5: Number of Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD)

Figure 6: Number of Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD)

Figure 7: Number of Products under Development for Idiopathic Pulmonary Fibrosis

Figure 8: Number of Products under Development by Companies, Idiopathic Pulmonary Fibrosis

Figure 9: Number of Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis

Figure 10: Number of Products by Top 10 Targets, Asthma

Figure 11: Number of Products by Stage and Top 10 Targets, Asthma

Figure 12: Number of Products by Top 10 Mechanism of Actions, Asthma

Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Asthma

Figure 14: Number of Products by Top 10 Routes of Administration, Asthma

Figure 15: Number of Products by Stage and Top 10 Routes of Administration, Asthma

Figure 16: Number of Products by Top 10 Molecule Types, Asthma

Figure 17: Number of Products by Stage and Top 10 Molecule Types, Asthma

Figure 18: Number of Products by Top 10 Targets, Chronic Obstructive Pulmonary Disease (COPD)

Figure 19: Number of Products by Stage and Top 10 Targets, Chronic Obstructive Pulmonary Disease (COPD)

Figure 20: Number of Products by Top 10 Mechanism of Actions, Chronic Obstructive Pulmonary Disease (COPD)

Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Obstructive Pulmonary Disease (COPD)

Figure 22: Number of Products by Top 10 Routes of Administration, Chronic Obstructive Pulmonary Disease (COPD)

Figure 23: Number of Products by Stage and Top 10 Routes of Administration, Chronic Obstructive Pulmonary Disease (COPD)

Figure 24: Number of Products by Top 10 Molecule Types, Chronic Obstructive Pulmonary Disease (COPD)

Figure 25: Number of Products by Stage and Top 10 Molecule Types, Chronic Obstructive Pulmonary Disease (COPD)

Figure 26: Number of Products by Top 10 Targets, Idiopathic Pulmonary Fibrosis

Figure 27: Number of Products by Stage and Top 10 Targets, Idiopathic Pulmonary Fibrosis

Figure 28: Number of Products by Top 10 Mechanism of Actions, Idiopathic Pulmonary Fibrosis

Figure 29: Number of Products by Stage and Top 10 Mechanism of Actions, Idiopathic Pulmonary Fibrosis

Figure 30: Number of Products by Routes of Administration, Idiopathic Pulmonary Fibrosis

Figure 31: Number of Products by Stage and Routes of Administration, Idiopathic Pulmonary Fibrosis

Figure 32: Number of Products by Top 10 Molecule Types, Idiopathic Pulmonary Fibrosis

Figure 33: Number of Products by Stage and Top 10 Molecule Types, Idiopathic Pulmonary Fibrosis

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$11985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards